registration07.05.2019 08:00:00 CET
Company announcement, Helsinki, 7 May 2019 at 9.00 AM
Nexstim Plc: Offer shares have been registered
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), has completed a rights issue which ended on 24 April 2019 in Sweden and on 26 April 2019 in Finland ("Offering"). The Company announced the final outcome of the rights issue on 2 May 2019 and as set forth in such announcement a total of 31 202 364 new shares of the Company have been registered to the Trade Register today 7 May 2019.
Pursuant to the registration of the shares issued in the Offering within the Trade Register, the number of shares in the Company is 34 461 869 (not the number set forth in the company announcement dated 2 May 2019 which excluded the 5,759 shares registered within the Trade Register on 28 March 2019 as part of the Company's restricted share unit plan).
The trading of the shares subscribed in the Offering will begin approximately on 8 May 2019 in First North Finland and approximately 9 May 2019 in First North Sweden.
NEXSTIM PLC
Martin Jamieson, CEO
Further information is available on the website www.nexstim.com or by contacting:
Martin Jamieson, Chairman and CEO
+44 771 516 3942
martin.jamieson@nexstim.com
Sisu Partners Oy (Certified Adviser)
Jussi Majamaa
+ 358 40 842 4479
jussi.majamaa@sisupartners.com
Citigate Dewe Rogerson
David Dible/Shabnam Bashir/ Sylvie Berrebi
+44 (0)207 2822949
david.dible@citigatedewerogerson.com
About Nexstim Plc
Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBTŪ) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.
Nexstim's NBTŪ system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBTŪ system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.
For more information please visit www.nexstim.com